← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #265 OF 1,000 MOST-CITED

Procedure Deviations Recorded and Justified

FDA cited this observation 111 times across 110 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs111
BY FISCAL YEAR
FY20264
FY20259
FY20245
FY202313
FY202211
FY20215
FY20207
FY201911
FY201815
FY201717
FY201614

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.2× the rate of the average FDA-cited firm (24.6% vs 7.7%), across 110 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Deviations from written production and process control procedures are not recorded and justified.

New SPS Crossfolds, LLC · Commack, New York · Drugs · 2026-04-20

Deviations from written production and process control procedures are not recorded.

Baxter Healthcare Corporation · Round Lake, Illinois · Drugs · 2026-04-02

Deviations from written production and process control procedures are not recorded and justified.

ONY Biotech, Inc. · Amherst, New York · Drugs · 2026-02-05

Deviations from written production and process control procedures are not.

Weckerle Cosmetics USA, INC · Torrance, California · Drugs · 2025-10-31

Deviations from written production and process control procedures are not justified.

Nippon Shikizai, Inc. · Tsukuba · Drugs · 2025-09-12

Deviations from written production and process control procedures are not recorded.

Noble Pharma, LLC · Menomonie, Wisconsin · Drugs · 2025-08-22

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →